PharmaCyte Biotech Inc (PMCB)

[Triple9]

well deserved bump

Janssen Pharmaceuticals will be our partner, imho.

The path that has led me to this conclusion is as follows, in chronological order:

First the NDA's were signed: http://pharmacyte.com/pharmacyte-seeks-to-solve-pancreas-puzzle-with-cell-in-a-box/ "... the company also is assessing the interest of big pharmas, and many have signed non-disclosure agreements."

Followed with a pr regarding Johnson & Johnson: http://ir.pharmacytebiotech.com/press-releases/detail/82/johnson-johnson-and-big-pharma-could-find-a-diabetes

PharmaCyte then hired a former J & J exec: http://ir.pharmacytebiotech.com/press-releases/detail/94/pharmacyte-biotech-appoints-former-johnson-johnson

KW then publicly posted on FB, (prior to taking his FB account private due to slanderous attacks on his person), that "150 years and still going strong according to my Canadian colleagues. At PharmaCyte, they will soon outnumber the Americans."

Followed by Bavarian Nordic's recent expansion deal with Janssen: https://finance.yahoo.com/news/bavarian-expands-j-j-deal-084519162.html

Bavarian Nordic is the forerunner to Austrianova: http://ir.pharmacytebiotech.com/press-releases/detail/29/pharmacyte-biotechs-cancer-treatment-tumor

J & J is the parent company of Janssen Pharmaceuticals. J & J has the largest presence in Canada of all pharmaceutical companies: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html

All the while, PharmaCyte attained Orphan Drug Designation from both the FDA and EMA. Additionally, a successful pre-IND meeting with the FDA resulted in the FDA recommendation that the upcoming trial in LAPC be upgraded from exploratory to pivotal status, providing PharmaCyte the opportunity for marketing approval.

My friends, this is the path which has led me to my conclusion. You are free to draw your own conclusions, I have simply provided the dd for those unwilling/unable to perform. GLTA!